samedan logo
 
 
 
spacer
home > ebr > autumn 2001 > biotechnology and patents from the finnish point of view
PUBLICATIONS
European Biopharmaceutical Review

Biotechnology and Patents From the Finnish Point of View

During the 80s and 90s, there was a remarkable investment boom in Finland in the biotechnological sector, and this trend is still continuing. With more than 115 biotechnology companies, Finland can be ranked amongst the top European countries in terms of number of biotechnological firms.Biotechnology comprises a large sector. Approximately half the businesses operating in Finland concentrate on health products such as pharmaceuticals. In general terms, the use of biotechnology in the pharmaceutical industry is increasing. It is estimated that biotechnology has been used in every fifth new pharmaceutical brought onto the market.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics

San Diego, CA, 21 December 2021: Insightful Science, the software company enabling the Cloud for Scientific Discovery, announced today that it has completed the transaction to acquire Protein Metrics, Inc., a leading provider of biopharmaceutical protein characterization and proteomics analysis software. The acquisition expands the Company’s R&D value chain to widen the biopharmaceutical protein analysis arena, unblocking data analysis bottlenecks currently associated with large-scale protein studies.
More info >>

White Papers

Outsourcing and Insourcing: How Eurofins solves the bio/pharma industry’s challenges associated with meeting drug development timelines and budgets with restricted headcounts

Eurofins BioPharma Product Testing

Pharmaceutical and biopharmaceutical companies face a significant challenge to get their drug products developed and launched quickly, all while keeping development costs down. One of the most common ways for companies to lower development costs is to manage fixed headcounts. But when the same scope of work still needs to be completed by a designated time with fewer staff members, this presents a significant challenge. So, how do bio/pharma companies solve this ever so common challenge of increasing output while decreasing headcount? There are essentially three options: temporary staffing, outsourcing, or insourcing.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement